After publishing a study evaluating Theranos' medical tests, the researchers are intending to collaborate with the company.
On Monday, the Journal of Clinical Investigation published a study that said Theranos reports more measures outside of their normal range when compared to measurements from the two largest testing labs in the U.S., Quest Diagnostics and LabCorp. Last week, Theranos sent a letter to the journal raising issues with sample collection methodology as well the lack of a detailed protocol.
Theranos told CNBC that it would like the researchers to share their data and protocols with them so that they can give a more scientific response to the study.
"Theranos believes in open access and greater transparency in lab testing. It's difficult to review a study in days that took over nine months to report, and in order for us to provide the kind of thoughtful and scientific response that it deserves, we call on the authors of the study to grant us access to the entire set of raw data and detailed protocols missing from the article," said Daniel Young, laboratory director and vice president at Theranos.
Joel Dudley, assistant professor of genetics and genomics at the Icahn School of Medicine at Mount Sinai, told CNBC's "Closing Bell" that he and his co-authors plan to provide that information.
"That's how good science is done. So, in the coming weeks, we're going to release the full data set that was the basis of the study in addition the software code and statistical code that generated all the figures and results of the study as well will be put in the public domain," he said.
As for the variability in Theranos' results, Dudley explained that the degree to which these measurements would affect clinical decisions depends on the individual physician. He said that these clinicians would also have to "take into account patient characteristics and the clinical situation."
Ultimately, Dudley remains optimistic about the direct-to-consumer health-care space and encourages additional research on these new forms of medical testing.
"We were initially excited about Theranos and Theranos technology and how we might use it in next-generation medicine," Dudley said. "The cost savings are really important as we go into capitated medicine and accountable care and things like that. There's huge opportunities for wellness," he said.